June 04, 2021
Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.
A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.
Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.
Findings from the phase 3 RELATIVITY-047 trial were presented at the 2021 ASCO Annual Meeting.
June 01, 2021
The FDA has approved sotorasib (Lumakras; Amgen Inc) for the treatment of non-small cell lung cancer in patients with KRAS G12C genetic mutations and who have received at least 1 prior therapy.
May 19, 2021
A session from the 2021 PQA Annual Meeting highlighted the benefits of virtual outreach in advancing patient care amid the COVID-19 pandemic and beyond.
May 11, 2021
Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
April 29, 2021
The future of clinical trials in a post pandemic world will rely on a patient-centered approach. Pharmacists can play a role to caring for these patients.
April 28, 2021
A session held at the HOPA Annual Meeting 2021 discussed investigational cancer drugs in clinical trials.
April 23, 2021
A session held at the HOPA Annual Meeting 2021 discussed best practices for optimizing opioid treatment in patients with cancer pain.
